Item 5.02 Departure of Directors or Certain Officers; Election of Directors;

Appointment of Certain Officers; Compensatory Arrangements of Certain

Officers.

On February 22, 2022, the Compensation Committee (the "Committee") of the Board of Directors of ChemoCentryx, Inc. (the "Company") approved an increase to the base salaries to be paid to the named executive officers listed below (the "NEOs"), effective January 1, 2022 in the amount of 4% to Thomas Schall, Tausif Butt, Susan Kanaya and Markus Cappel and 1% to Rita Jain (reflecting proration based upon her October 5, 2021 start date as Chief Medical Officer). On February 22, 2022, the Committee also approved cash bonuses to be paid to the NEOs listed below for the 2021 fiscal year and approved and awarded the stock options and restricted stock units listed below to the NEOs under the Company's the Amended and Restated 2012 Equity Incentive Award Plan. The exercise price per share of such stock options is $29.83, the closing price per share of the Company's common stock on the Nasdaq Global Select Market on February 22, 2022. Twenty-five percent of the total number of shares of common stock subject to each NEO's option will vest on January 1, 2023, and 1/48th of the total number of shares of common stock subject to such option will vest monthly thereafter, subject to such NEO's continued employment or service relationship with the Company on each such vesting date. One fourth of each of the NEO's restricted stock unit awards will vest on January 1, 2023, and the remaining three fourths of each of the NEO's restricted stock unit awards will vest on January 1, 2024, January 1, 2025 and January 1, 2026, respectively, subject to such NEO's continued employment or service relationship with the Company on each such vesting date.



The 2021 actual cash bonus payments, stock option grants and restricted stock
unit awards are as follows:

                                                                                      Restricted
                                                      2021 Actual        Stock        Stock Unit
      Name                      Title                 Cash Bonus        Options         Awards
Thomas J.          President and Chief Executive
Schall, Ph.D.      Officer                           $     464,563       192,600          152,700
Tausif Butt        Executive Vice President, Chief
                   Operating Officer                 $     180,000        52,200           41,400
Rita Jain,         Executive Vice President, Chief
M.D.(1)            Medical Officer                   $      65,625        14,700           11,600
Susan M. Kanaya    Executive Vice President, Chief
                   Financial and Administrative
                   Officer and Secretary             $     298,872        75,200           59,700
Markus J.          Chief Business Officer
Cappel, Ph.D.                                        $     175,443        51,400           40,700

(1) Dr. Jain's cash bonus and equity awards reflect proration based upon her

October 5, 2021 start date as Chief Medical Officer.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses